NTLA vs. PRME

In the year-to-date period, NTLA achieves a -41.08% return, which is significantly higher than PRME's -59.59% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Prime Medicine Inc. Common Stock (PRME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NTLA Sharpe Ratio is -0.89, which is comparable to the PRME Sharpe Ratio of -0.84. The chart below compares the historical Sharpe Ratios of NTLA and PRME, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NTLA nor PRME has paid dividends to shareholders.

The maximum NTLA drawdown since its inception was -96.45%, roughly equal to the maximum PRME drawdown of -94.55%. Use the drawdown chart below to compare losses from any high point for NTLA and PRME.

The current volatility for Intellia Therapeutics, Inc. (NTLA) is 38.04%, while Prime Medicine Inc. Common Stock (PRME) has a volatility of 40.33%. This indicates that NTLA experiences smaller price fluctuations and is considered to be less risky than PRME based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Prime Medicine Inc. Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.